The Sigma1R agonist and muscarinic receptor modulator ANAVEX2-73 (blarcamesine) [181,364] is in a phase 2/3 study for patients with early AD (NCT04314934, NCT03790709), phase 2 for PD patients with dementia (NCT04575259). This evidence concerns the gene SIGMAR1 and Alzheimer disease.